Literature DB >> 28444080

Rhabdomyolysis as a manifestation of a metabolic disease: a case report.

Marta Sousa Moniz1, Maria Inês Mascarenhas1, Carlos Escobar1, Pedro Nunes1, Clara Abadesso1, Helena Loureiro1, Helena Almeida1.   

Abstract

Rhabdomyolysis is a process of muscle destruction that can present with varying clinical manifestations. In pediatric patients, its main etiology is infectious diseases. We present a previously healthy adolescent who was admitted to our emergency department with a four-day history of myalgia, muscle weakness and dark urine. At presentation, she was dehydrated. Blood analysis revealed acute renal failure and increased muscular enzymes. She was transferred to our pediatric intensive care unit. Medical therapies for correction of dehydration and the ionic and metabolic consequences of renal failure were performed. Due to oliguria, renal replacement therapy was initiated. An etiological investigation revealed a beta-oxidation defect. Metabolic diseases are a known cause of rhabdomyolysis. Muscular destruction should be diagnosed early in order to avoid its potential consequences. Generally, the treatment of rhabdomyolysis is conservative, although in some situations, a more invasive approach is needed.

Entities:  

Mesh:

Year:  2017        PMID: 28444080      PMCID: PMC5385993          DOI: 10.5935/0103-507X.20170016

Source DB:  PubMed          Journal:  Rev Bras Ter Intensiva        ISSN: 0103-507X


  9 in total

1.  Rhabdomyolysis caused by an inherited metabolic disease: very long-chain acyl-CoA dehydrogenase deficiency.

Authors:  Nicol C Voermans; Baziel G van Engelen; Leo A Kluijtmans; Nike M Stikkelbroeck; Ad R Hermus
Journal:  Am J Med       Date:  2006-02       Impact factor: 4.965

Review 2.  Continuous renal replacement therapy (CRRT) for rhabdomyolysis.

Authors:  Xiaoxi Zeng; Ling Zhang; Taixiang Wu; Ping Fu
Journal:  Cochrane Database Syst Rev       Date:  2014-06-15

3.  Acute pediatric rhabdomyolysis: causes and rates of renal failure.

Authors:  Rebekah Mannix; Mei Lin Tan; Robert Wright; Marc Baskin
Journal:  Pediatrics       Date:  2006-11       Impact factor: 7.124

Review 4.  The syndrome of rhabdomyolysis: complications and treatment.

Authors:  Yiannis S Chatzizisis; Gesthimani Misirli; Apostolos I Hatzitolios; George D Giannoglou
Journal:  Eur J Intern Med       Date:  2008-04-28       Impact factor: 4.487

5.  A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency.

Authors:  Georgianne L Arnold; Johan Van Hove; Debra Freedenberg; Arnold Strauss; Nicola Longo; Barbara Burton; Cheryl Garganta; Can Ficicioglu; Stephen Cederbaum; Cary Harding; Richard G Boles; Dietrich Matern; Pranesh Chakraborty; Annette Feigenbaum
Journal:  Mol Genet Metab       Date:  2009-01-20       Impact factor: 4.797

Review 6.  State of the art in muscle lipid diseases.

Authors:  W C Liang; I Nishino
Journal:  Acta Myol       Date:  2010-10

Review 7.  Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians.

Authors:  Ana L Huerta-Alardín; Joseph Varon; Paul E Marik
Journal:  Crit Care       Date:  2004-10-20       Impact factor: 9.097

8.  Myoglobin clearance by super high-flux hemofiltration in a case of severe rhabdomyolysis: a case report.

Authors:  Toshio Naka; Daryl Jones; Ian Baldwin; Nigel Fealy; Samantha Bates; Hermann Goehl; Stanislao Morgera; Hans H Neumayer; Rinaldo Bellomo
Journal:  Crit Care       Date:  2005-01-21       Impact factor: 9.097

9.  Haff disease associated with the ingestion of the freshwater fish Mylossoma duriventre (pacu-manteiga).

Authors:  Oswaldo Tolesani Júnior; Christian Nejm Roderjan; Edgard do Carmo Neto; Micheli Mikaeli Ponte; Mariana Cristina Pelli Seabra; Marcos Freitas Knibel
Journal:  Rev Bras Ter Intensiva       Date:  2013 Oct-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.